Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFMRN8)

Drug Name
18beta-Glycyrrhetic acid Drug Info
Synonyms
18b-Glycyrrhetic acid; CHEMBL208873; 18b-Glycyrrhetinic acid; Glycyrrhetinic Acid, 8; 18; A-Glycyrrhetintic Acid; SCHEMBL231125; BDBM23195; pentacyclic triterpene compound 8; MolPort-023-220-126; AKOS016009607; cent-GLYCYRRHETINTIC ACID; AS-11631; SC-17800; (2S,4aS,6aS,6bR,10S,12aS,12bR,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10114
ChEBI ID
CHEBI:30853
CAS Number
CAS 471-53-4
TTD Drug ID
DMFMRN8

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting PTPN1 messenger RNA (PTPN1 mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [6]
TRYPAN BLUE DM4NTMO Ophthalmic surgery injury PK97 Approved [7]
URSOLIC ACID DM4SOAW Metabolic syndrome x 5C50-5D2Z Phase 2 [8]
ISIS 113715 DMUPD4G Type-2 diabetes 5A11 Phase 2 [9]
ISIS-PTP1Brx DMJGVXT Type-2 diabetes 5A11 Phase 2 [10]
ERTIPROTAFIB DMJXEV7 Type-2 diabetes 5A11 Terminated [11]
Acetate Ion DMD08RH Discovery agent N.A. Investigative [12]
B-Octylglucoside DMMO75G Discovery agent N.A. Investigative [12]
2-Methyl-2,4-Pentanediol DMD45CU Discovery agent N.A. Investigative [12]
Double Oxidized Cysteine DM6TU84 Discovery agent N.A. Investigative [12]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member C4 (AKR1C4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [13]
Diazepam DM08E9O Alcohol withdrawal Approved [14]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [15]
Benzbromarone DMC3YUA Gout FA25 Approved [2]
Flufenamic Acid DMC8VNH Dysmenorrhea GA34.3 Approved [2]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [16]
Nitrazepam DMEGIQ6 Epilepsy 8A60-8A68 Approved [14]
Flunitrazepam DMGR5Z3 Insomnia 7A00-7A0Z Approved [14]
Chenodiol DMQ8JIK Cholelithiasis DC11 Approved [17]
Gamolenic acid DMQN30Z Allergy 4A80-4A85 Approved [18]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member C3 (AKR1C3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [19]
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [20]
Diazepam DM08E9O Alcohol withdrawal Approved [14]
Levonorgestrel DM1DP7T Atypical endometrial hyperplasia Approved [21]
Desogestrel DM27U4Y Contraception QA21 Approved [21]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [20]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [20]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [22]
Quercetin DM3NC4M Obesity 5B81 Approved [23]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [24]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member C2 (AKR1C2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [20]
Diazepam DM08E9O Alcohol withdrawal Approved [14]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [25]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [26]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [20]
Quercetin DM3NC4M Obesity 5B81 Approved [27]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [28]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [20]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [29]
Testosterone DM7HUNW Hot flushes GA30 Approved [30]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Aldo-keto reductase family 1 member C1 (AKR1C1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Amenorrhea GA20.0 Approved [31]
Meclofenamic acid DM05FXR Ankylosing spondylitis FA92.0 Approved [20]
Diazepam DM08E9O Alcohol withdrawal Approved [14]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [32]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [20]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [20]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [33]
Glimepiride DM5FSJA Diabetic complication 5A2Y Approved [34]
Ethacrynic acid DM60QMR Edema MG29 Approved [32]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [20]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Multidrug resistance-associated protein 1 (ABCC1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [35]
Folic Acid DMEMBJC Colorectal carcinoma Approved [36]
Methotrexate DM2TEOL Anterior urethra cancer Approved [37]
Quercetin DM3NC4M Obesity 5B81 Approved [38]
Docetaxel DMDI269 Advanced cancer 2A00-2F9Z Approved [39]
Irinotecan DMP6SC2 Adenocarcinoma 2D40 Approved [40]
Epirubicin DMPDW6T Solid tumour/cancer 2A00-2F9Z Approved [41]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [42]
Colchicine DM2POTE Acute gout flare FA25.0 Approved [43]
Dactinomycin DM2YGNW Adult kidney Wilms tumor Approved [43]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Renin (REN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ranitidine DM0GUSX Gastric ulcer DA60 Approved [44]
Acebutolol DM0TI4U Hypertension BA00-BA04 Approved [45]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [46]
Reboxetine DM26PRD Depression 6A70-6A7Z Approved [47]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [48]
Ramipril DM2R68E Acute heart failure BD10-BD13 Approved [49]
Rhucin DM3ADGP Erectile dysfunction HA01.1 Approved [50]
Naloxone DM3FXMA Narcotic depression 6A7Z Approved [51]
Epinephrine DM3KJBC Acute asthma CA23 Approved [52]
Chlorthalidone DM4DMBT Edema MG29 Approved [53]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By GTPase HRas (HRAS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [54]
Selenium DM25CGV N. A. N. A. Approved [55]
Deoxycholic acid DM3GYAL Subcutaneous fat disorder EF02 Approved [56]
Quercetin DM3NC4M Obesity 5B81 Approved [57]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [58]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [59]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [60]
Lovastatin DM9OZWQ Arteriosclerosis BD40 Approved [61]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [62]
Sevoflurane DMC9O43 Anaesthesia 9A78.6 Approved [63]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
PTPN1 messenger RNA (PTPN1 mRNA) TTELIN2 PTN1_HUMAN Inhibitor [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Aldo-keto reductase family 1 member C1 (AKR1C1) OTQKR4CM AK1C1_HUMAN Gene/Protein Processing [2]
Aldo-keto reductase family 1 member C2 (AKR1C2) OTQ2XMO3 AK1C2_HUMAN Gene/Protein Processing [2]
Aldo-keto reductase family 1 member C3 (AKR1C3) OTU2SXBA AK1C3_HUMAN Gene/Protein Processing [2]
Aldo-keto reductase family 1 member C4 (AKR1C4) OTW2MMOF AK1C4_HUMAN Gene/Protein Processing [2]
GTPase HRas (HRAS) OTWQN0DP RASH_HUMAN Gene/Protein Processing [3]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Gene/Protein Processing [4]
Renin (REN) OT52GZR2 RENI_HUMAN Gene/Protein Processing [5]

References

1 Protein tyrosine phosphatase 1B inhibitory activity of triterpenes isolated from Astilbe koreana. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3273-6.
2 Selective and potent inhibitors of human 20alpha-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone. Chem Biol Interact. 2003 Feb 1;143-144:503-13.
3 Selective cytotoxicity of glycyrrhetinic acid against tumorigenic r/m HM-SFME-1 cells: potential involvement of H-Ras downregulation. Toxicol Lett. 2010 Feb 15;192(3):425-30. doi: 10.1016/j.toxlet.2009.11.021. Epub 2009 Dec 1.
4 Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals. Cancer Chemother Pharmacol. 2008 Oct;62(5):867-73.
5 Inhibition of human renin activity by saponins. Biomed Res. 2010 Apr;31(2):155-9. doi: 10.2220/biomedres.31.155.
6 Periodinates: a new class of protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 1999 Feb 8;9(3):353-6.
7 Evans Blue and other dyes as protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1923-6.
8 Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9.
9 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
10 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
11 2-O-carboxymethylpyrogallol derivatives as PTP1B inhibitors with antihyperglycemic activity. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5357-60.
12 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
13 Initro CAPE inhibitory activity towards human AKR1C3 and the molecular basis. Chem Biol Interact. 2016 Jun 25;253:60-5.
14 Substrate specificity of human 3(20)alpha-hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. Biol Pharm Bull. 2002 Apr;25(4):441-5.
15 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
16 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
17 Chenodeoxycholic acid significantly impacts the expression of miRNAs and genes involved in lipid, bile acid and drug metabolism in human hepatocytes. Life Sci. 2016 Jul 1;156:47-56.
18 Antineoplastic effects of gamma linolenic Acid on hepatocellular carcinoma cell lines. J Clin Biochem Nutr. 2010 Jul;47(1):81-90.
19 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
20 Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase (AKR1C3): role in breast cancer and inhibition by non-steroidal anti-inflammatory drug analogs. Chem Biol Interact. 2009 Mar 16;178(1-3):221-7.
21 Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3. Chem Biol Interact. 2011 May 30;191(1-3):227-33.
22 In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics. 2008 Feb;18(2):109-20.
23 AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. Chem Biol Interact. 2009 Mar 16;178(1-3):138-44.
24 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
25 Gene expression after treatment with hydrogen peroxide, menadione, or t-butyl hydroperoxide in breast cancer cells. Cancer Res. 2002 Nov 1;62(21):6246-54.
26 A new in vitro method for identifying chemical sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human skin cells. Cutan Ocul Toxicol. 2010 Sep;29(3):171-92.
27 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
28 Aberrantly expressed genes in HaCaT keratinocytes chronically exposed to arsenic trioxide. Biomark Insights. 2011 Feb 8;6:7-16.
29 Thyroid hormone responsive genes in cultured human fibroblasts. J Clin Endocrinol Metab. 2005 Feb;90(2):936-43.
30 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
31 Progestin effects on expression of AKR1C1-AKR1C3, SRD5A1 and PGR in the Z-12 endometriotic epithelial cell line. Chem Biol Interact. 2013 Feb 25;202(1-3):218-25.
32 Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
33 Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007 Jun;98(6):890-9.
34 Initro inhibition of AKR1Cs by sulphonylureas and the structural basis. Chem Biol Interact. 2015 Oct 5;240:310-5.
35 Characterization of multidrug transporter-mediated efflux of avermectins in human and mouse neuroblastoma cell lines. Toxicol Lett. 2015 Jun 15;235(3):189-98. doi: 10.1016/j.toxlet.2015.04.005. Epub 2015 Apr 9.
36 Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
37 Methotrexate normalizes up-regulated folate pathway genes in rheumatoid arthritis. Arthritis Rheum. 2013 Nov;65(11):2791-802.
38 Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology. 2002 Feb 28;171(2-3):137-46.
39 Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. Int J Cancer. 2004 Sep 10;111(4):484-93. doi: 10.1002/ijc.20230.
40 Clinical determinants of response to irinotecan-based therapy derived from cell line models. Clin Cancer Res. 2008 Oct 15;14(20):6647-55.
41 Co-encapsulation of chrysophsin-1 and epirubicin in PEGylated liposomes circumvents multidrug resistance in HeLa cells. Chem Biol Interact. 2015 Dec 5;242:13-23. doi: 10.1016/j.cbi.2015.08.023. Epub 2015 Sep 1.
42 Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance. Hematology. 2007 Dec;12(6):511-7. doi: 10.1080/10245330701562535.
43 Functional analysis of MRP1 cloned from bovine. FEBS Lett. 2002 Jun 19;521(1-3):211-3. doi: 10.1016/s0014-5793(02)02816-8.
44 Effects of histamine H2-receptor blockade on the cardiovascular reflex response to lower-body negative pressure in man. Acta Physiol Scand. 1990 May;139(1):161-72. doi: 10.1111/j.1748-1716.1990.tb08909.x.
45 Addition of acebutolol to diuretics in hypertension. Clin Pharmacol Ther. 1981 Dec;30(6):739-44. doi: 10.1038/clpt.1981.232.
46 Relative potency of a beta-blocking and a calcium entry blocking agent as antihypertensive drugs in black patients. Eur J Clin Pharmacol. 1986;29(5):523-7. doi: 10.1007/BF00635887.
47 Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans. Hypertension. 2006 Jul;48(1):120-6. doi: 10.1161/01.HYP.0000225424.13138.5d. Epub 2006 May 22.
48 Effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis. Am J Med. 1990 Sep;89(3):313-21. doi: 10.1016/0002-9343(90)90344-d.
49 Effects of an angiotensin converting enzyme inhibitor, ramipril, on intracranial circulation in healthy volunteers. off. Br J Clin Pharmacol. 1992 Sep;34(3):224-30. doi: 10.1111/j.1365-2125.1992.tb04128.x.
50 Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites. Am J Physiol Renal Physiol. 2005 May;288(5):F1044-52. doi: 10.1152/ajprenal.00142.2004. Epub 2004 Dec 21.
51 beta-Endorphin and essential hypertension: importance of the clonidine-naloxone interaction. Acta Physiol Hung. 1985;65(2):217-26.
52 Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med. 1983 Dec 8;309(23):1414-9. doi: 10.1056/NEJM198312083092303.
53 Detection of low-renin hypertension; evaluation of out-patient renin-stimulating methods. Clin Sci Mol Med. 1975 Feb;48(2):91-6. doi: 10.1042/cs0480091.
54 Profiles of antioxidant/electrophile response element (ARE/EpRE) nuclear protein binding and c-Ha-ras transactivation in vascular smooth muscle cells treated with oxidative metabolites of benzo[a]pyrene. Biochem Pharmacol. 2000 Nov 1;60(9):1285-96.
55 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
56 Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: roles of Ras, p38, and CCAAT/enhancer-binding protein. Nutr Cancer. 2008;60(3):389-400.
57 Quercetin inhibits p21-RAS expression in human colon cancer cell lines and in primary colorectal tumors. Int J Cancer. 2000 Feb 1;85(3):438-45.
58 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
59 A comprehensive analysis of Wnt/beta-catenin signaling pathway-related genes and crosstalk pathways in the treatment of As2O3 in renal cancer. Ren Fail. 2018 Nov;40(1):331-339.
60 Poly(ADP-ribosyl)ation enhances H-RAS protein stability and causes abnormal cell cycle progression in human TK6 lymphoblastoid cells treated with hydroquinone. Chem Biol Interact. 2015 Aug 5;238:1-8. doi: 10.1016/j.cbi.2015.05.019. Epub 2015 Jun 3.
61 Combining prenylation inhibitors causes synergistic cytotoxicity, apoptosis and disruption of RAS-to-MAP kinase signalling in multiple myeloma cells. Br J Haematol. 2005 Sep;130(6):912-25. doi: 10.1111/j.1365-2141.2005.05696.x.
62 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
63 The differential cancer growth associated with anaesthetics in a cancer xenograft model of mice: mechanisms and implications of postoperative cancer recurrence. Cell Biol Toxicol. 2023 Aug;39(4):1561-1575. doi: 10.1007/s10565-022-09747-9. Epub 2022 Aug 12.